首页> 外文期刊>Epidemiology and infection >A prospective study of women with ASCUS or LSIL pap smears at baseline and HPV E6/E7 mRNA positive: a 3-year follow-up
【24h】

A prospective study of women with ASCUS or LSIL pap smears at baseline and HPV E6/E7 mRNA positive: a 3-year follow-up

机译:对基线时患有ASCUS或LSIL巴氏涂片且HPV E6 / E7 mRNA阳性的女性进行的前瞻性研究:3年随访

获取原文
           

摘要

Human papillomavirus (HPV) testing is used in the triage of women with a borderline smear result. The efficiency of testing women with a low-grade squamous intraepithelial lesion (LSIL) and atypical squamous cells of undetermined significance (ASCUS) is less clear. For this reason we used a new HPV test that detects E6/E7 messenger RNA (mRNA), which might have a higher specificity. The objective of this prospective study was to assess whether HPV E6/E7 mRNA positivity in women with ASCUS and LSIL at baseline, is able to predict those women who have a high risk of developing a histological cervical intraepithelial neoplasia (CIN2) or worse lesion. We took into consideration the women's age and HPV DNA genotype and followed them up for 3 years. Cervical samples from women with high-risk HPV (HR-HPV) DNA-positive ASCUS (n = 90) or LSIL (n = 222) were tested for the presence of HR-HPV E6/E7 mRNA and the women were monitored for the development of histopathologically verified CIN2+. Thirteen patients with ASCUS and 17 with LSIL did not complete follow-up. All patients with LSIL and ASCUS, enrolled in this study, had confirmed lesions at the colposcopic examination. Follow-up was available for 312 women, 193 were positive in the HR-HPV DNA test and 93 had a HPV E6/E7 mRNA positive test. Finally, 22 women positive in the HPV DNA test for high-risk genotypes and with positive E6/E7 mRNA had a histologically confirmed CIN2+. Only two cases with negative HPV E6/E7 mRNA had CIN2+. The study shows that women positive in the HPV E6/E7 mRNA test have a greater risk of malignant progression of cervical lesions and therefore deserve greater attention and earlier check-ups.
机译:人类乳头瘤病毒(HPV)测试用于对女性进行分流,涂片结果不佳。对患有低度鳞状上皮内病变(LSIL)和意义不明的非典型鳞状细胞(ASCUS)的女性进行测试的效率尚不清楚。因此,我们使用了一种新的HPV测试,该测试可检测到可能具有更高特异性的E6 / E7信使RNA(mRNA)。这项前瞻性研究的目的是评估基线时患有ASCUS和LSIL的女性中HPV E6 / E7 mRNA阳性是否能够预测那些有发生组织学性宫颈上皮内瘤变(CIN2)或病灶更严重的女性。我们考虑了妇女的年龄和HPV DNA基因型,并对其随访了3年。检测高危HPV(HR-HPV)DNA阳性ASCUS(n = 90)或LSIL(n = 222)妇女的宫颈样本中是否存在HR-HPV E6 / E7 mRNA,并对妇女进行监测。组织病理学验证的CIN2 +的开发。 13名ASCUS患者和17名LSIL患者未完成随访。参加这项研究的所有LSIL和ASCUS患者在阴道镜检查中均已确认病变。对312名妇女进行了随访,HR-HPV DNA测试中有193例阳性,HPV E6 / E7 mRNA测试中有93例阳性。最终,在HPV DNA测试中表现出高风险基因型且E6 / E7 mRNA阳性的22名女性在组织学上证实了CIN2 +。只有两个HPV E6 / E7 mRNA阴性的病例具有CIN2 +。研究表明,在HPV E6 / E7 mRNA检测中呈阳性的妇女宫颈病变的恶性发展风险更高,因此应引起更多关注和更早检查。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号